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AGS:   anterior glottic stenosis  
AR:  allergic rhinitis 
CD4+:  a major classification of T 
lymphocytes, referring to 
those that carry the CD4 
antigen; most are helper 
cells, also called CD4 T 
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CI:   confidence interval; 
COPD:  chronic obstructive 
pulmonary disease,  
CRS:  chronic rhinosinusitis 
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NIPF:  nasal inspiratory peak flow 
NKFP:  Nemzeti Kutatási és 
Technológiai Hivatal 
NO:  nasal obstruction 
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Normal T Expressed and 
Secreted 
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S:  sneezing 
SNP:  sinle nucleotid 
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SZTE: University of Szeged 
TGFβ1:  transforming growth factor β1;  
TNS:   total nasal score  
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molecule-1 
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INTRODUCTION AND AIMS: 1 
Inflammatory diseases of the airways are illnesses of high incidence affecting large 2 
populations, bearing great social and economical importance by having an impact on 3 
workplace and at-home activities as well as the quality of life.  Anatomical structures such as 4 
the nasal cavity, the larynx, the trachea and the lower airways taking part in breathing 5 
contribute to ensure physiological breathing as a whole unit, therefore their diseases develop 6 
more and more obviously in clinical practice, in correlation with each other. The concept of 7 
’one airway, one disease’ has also been declared by the WHO ARIA document (12).  8 
Being the gateway in the air flow for breathing, the nose plays an indispensable part in 9 
the homeostasis of the s. It warms, humidifies and filtrates air, thus protecting the lower 10 
airways. The nose and the bronchial systems are anatomically connected to each other. Their 11 
surface and histological structures are similar as both areas are covered with multilayered 12 
ciliary epithelium almost everywhere, and they are in contact by means of numerous indirect 13 
neural and systemic mechanisms, too. The nature of the nasobronchial link and the 14 
nasobronchial reflex has yet not been fully cleared, however, it is a fact that nasal diseases 15 
(allergic rhinitis, nasal polyposis, common cold) resulting the release of inflammatory 16 
mediators may have a consequence on the lower airway, too. The link studied the most is the 17 
one between allergic rhinitis and asthma.  18 
We have launched several projects for the study of diseases of the airways, in 19 
cooperation with joint work groups of the Department of Oto-Rhino-Laryngology and Head-20 
Neck Surgery at the University of Szeged, the Department of Dermatology and Allergology, 21 
and the Institute of Pathology. We have researched pathophysiologically similar molecular 22 
biological processes which nevertheless presented differrent symptoms based on their 23 
anatomical localization. As a practicing clinician, during my work my primary aim and task 24 
was to study and introduce the application opportunities in practice of already acquired 25 
knowledge in the field of clinical diagnostics and therapy.  26 
 27 
1. In the past 20 years, our clinic has become of the the leading centers in Hungary in the 28 
treatment of scarry airway stenosis in adults and children. In the case of large airway stenosis, 29 
some external agent causes the mechanical damage of the endotracheal mucosa. The often 30 
iatrogenic cause (mispositioned tracheotomy, long term intubation), initiates an inflammatory 31 
cascade mechanism, which then results scarring in the pursuit of restitution. In reference to 32 
cricotracheal resection introduced in patients with laryngeal and/or tracheal stenosis, we had 33 
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the opportunity to conduct a histological study of the removed surgical specimens. By means 34 
of the increase of „minimally invasive” endotracheal interventions preceding resection aimed 35 
at the elimination of acute asphyxia, the inflammatory cell infiltration and scar tissue 36 
formation affects deeper and deeper tissue layers. Particularly apparent is the large fibrosis 37 
extending to all tissue layers of the trachea observable during the CO2 laser vaporisation(s) 38 
with increased number and extension, which manifests in an increased clinically stenosis 39 
predisposition. Histological examinations even in patients classified in the same group 40 
showed large individual differences. Individually patient-dependant, genetically determined 41 
molecular biological mechanisms affecting the inflammatory base process stand behind the 42 
scar formation, which has thus far been explained with exogeneous causes. Recognition of 43 
these processes result the creation of new diagnostic and therapeutic modalities. Diseases with 44 
airway scarring can be related to the expression and polymorphism of certain determined 45 
genes, just as it was suspected earlier in connection with fibrotic diseases of airways or other 46 
organs (1)  47 
 48 
2.  Ultraviolet (UV) light is one of the major environmental hazards, and its role is well-49 
known in the triggering of skin tumors and skin aging. However, phototherapy (UV and 50 
visible light (VIS) has a significant local and systemic immunosuppressive effect, therefore it 51 
has been broadly used as a remedy for the treatment of various inflammatory, immune-52 
mediated skin diseases (2,3). Phototherapy exerts its immunosuppressive effect in the skin by 53 
means of inducing T-cells apoptosis, inhibiting the number and function of Langerhans cells 54 
and increasing the quantity of immunomodulatory cytokines (IL-10) (4,5). Our research 55 
results suggest that irradiating the nasal mucosa with light of different wavelengths (UV and 56 
visible, mUV/VIS) is efficient in reducing the symptoms of allergic rhinitis (6-8). Based on 57 
the above results, the Hungarian Medical Research Council (ETT TUKEB) declared  the 58 
mUV/VIS-based therapy of allergic rhinitis to be a medical procedure (file no.: 351/KO/02, 59 
certificate no.: 60008/20/ETT/2002). The Rhinolight® phototherapeutic device used for the 60 
treatment is a CE-marked medical device. The efficacy of the Rhinolight® intranasal 61 
phototherapy in seasonal allergic rhinitis was justified by our research work group using a 62 
randomized, double-blind, placebo-controlled clinical study (8-11). Positive therapeutic 63 
experience gained in the treatment of chronic immune-mediated diseases of the nasal mucosa 64 
inspired the creation of new phototherapeutic protocols and the designation of new indication 65 
areas and target groups. 66 
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Allergic rhinitis (AR) has become by now the most common chronic disease 67 
worldwide (12), with an estimated number of patients to be over 500 million. According to 68 
WHO figures, half of Europe’s population can become hay fever sufferer by 2015 due to the 69 
global and explosive growth of incidence. Studies for prevalence in Hungary also reported on 70 
a significant increase (13-14). In addition, its social and economic importance is further 71 
intensified as severe and/or persistent cases increase asthma prevalence, remarkably constrain 72 
nighttime resting and daytime activities, which cause additional decline in the quality of life. 73 
The success of all initiatives for prevention, primarily aimed at the change of lifestyle and 74 
environment is doubtful, due to the lack of widespread social inclusion. Currently, the most 75 
successful way of alleviating the harmful consequences can be the application of effective 76 
treatment modalities.  77 
The group of CRS disorders annually accounts as many as 22 million office visits and 78 
more than 500,000 emergency department visits in the U.S., according to some estimates. 79 
Annual CRS-related healthcare expenditures may reach as much as $3.5 billion (15). 80 
Inflammation of viral or bacterial origin are the most frequent of the above. On some 81 
occasions special and rare forms may develop, which primarily present differentialdiagnostic 82 
difficulties (16). Nevertheless, despite having established a proper diagnosis and following 83 
the therapeutic principles, we often experience treatment failure. 84 
Nasal polyposis appear in some 20% of chronic rhinosinusitis patients. In developed 85 
countries, also in Hungary, nasal polyposis is a disease affecting large population, 86 
characterized by a high recurrence rate, bad recovery inclination, and significantly reduced 87 
quality of life. Depending on different sociocultural and environmental impacts, these days its 88 
prevalence varies between 1,3-5,6%. 20-25% occurence was documented after block 89 
dissection in cadavers, therefore the pathological deformation is much more frequent than that 90 
of the diagnozed and treated cases. Treatment of nasal polyposis has still not been solved until 91 
now. Recurrence of polyps is still high even under the generally accepted combined, surgical-92 
steroid treatment strategy, so neither surgical treatment, nor steroid therapy administered in 93 
the long run, but not even their combination can result total recovery of the patient (17). Even 94 
the application of further conservative treatment modalities (nasal lavage, long-term low-dose 95 
systemic macrolid antibiotics and local antimycotics, aspirin desensitization, anti-IgE, anti-IL-96 
5, etc.) cannot offer a final solution. Also, it poses a problem that possible complications and 97 
side-effects of both surgery and the steroid treatment are known.  98 
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Histological characteristics of nasal polyposis very much resembles that of certain 99 
other immunological skin diseases of proliferative nature (eg. psoriasis), which have already 100 
been successfully treated with PUVA for some 30 years now (per os combined use of UVA-101 
light and 8-methoxypsoralen photosensitizer). The intranasal PUVA treatment significantly 102 
reduced nasal symptoms of allergic rhinitis patients (18). During our preliminary, open- label, 103 
prospective clinical study, we however did not manage to achieve macroscopic change after a 104 
6-week PUVA treatment, yet we experienced a significant reduction of eosinophil cationic 105 
protein (ECP) and IL-5 levels in the nasal lavage, also a significant decrease of eosinophils in 106 
the polyp tissue. (19). Similar etiological factors of allergic diseases and the favorable 107 
experience in the application of intranasal PUVA treatment hold out promising results and 108 
inspire further development of UV phototherapy and the examination of its use in nasal 109 
polyposis. 110 
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MY DUTIES AND AIMS IN THIS COMPLEX STUDY WERE: 111 
 112 
1.1. Histopathological examinations of stenotic and scarry trachea specimens removed 113 
using cricotracheal resection. 114 
1.2. Examination of TGFβ superfamily playing a decisive role in the regulation of 115 
inflammatory processes, and the predisposition role of its various poyimorphisms in the 116 
formation of laryngotracheal scarring. 117 
 118 
2.1. The basic condition for the application of the new, promising phototherapeutic 119 
treatment was the exclusion of the nasal mucosa damaging effect of UV beams used in the 120 
therapeutic range and dose (Justification of safe usability). Evaluation the in vivo effect of 121 
intranasal phototherapy, by assessing DNA damage and repair mechanism in nasal 122 
mucosa. 123 
2.2. So far, little experience has been available regarding its applicability in persistent 124 
allergic rhinitis (PAR). The aim of our research executed with the support of the Jedlik Ányos 125 
Programme (NKFP1-00004/2005) during a human, randomized, double-blind, placebo-126 
controlled, prospective clinical study was the development of a new RL-therapeutic protocol, 127 
and the establishment of its efficacy and safe usability in the treatment of PAR. (Ethical 128 
licence: SZTE, Regional Human Medical Biological Research Ethics Committee, file no.: 129 
110/2007, permit no.: 2288.).  130 
2.3.  Our experimental histological studies have justified that UVB penetrates well in vivo 131 
into the polyp tissue, it reaches in the stroma the lymphocytes responsible for the 132 
inflammation, and induces apopotosis in them. On the basis of these results, the objective of 133 
our clinical studies: To examine the clinical efficacy and tolerability of NB-UVB 134 
phototherapy in bilateral nasal polyps 135 
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1. HISTOPATHOLOGICAL AND MOLECULAR BIOLOGICAL STUDIES OF 136 
DISEASES WITH SCAR FORMATION IN THE AIRWAY 137 
1.1. Histopathological and molecular biological studies of processes with 138 
laryngotracheal scarring 139 
1.1.1. Introduction  140 
Air enters the lung through the larynx and the trachea, thus, any obstruction of this 141 
area leads to either asphyxia, or in severe cases, to the drop in the quality of life or to a state 142 
incompatible with life. The most frequent type of the stenosis is the intraluminar scar 143 
formation due to the injuries of airways tissue or anatomical structures. Until the mid-XX. 144 
century, the most frequent cause of the scarry stenosis of the upper airways were external 145 
neck traumas and infectious diseases which recover with scars (e.g. diphtheria, syphilis etc.). 146 
However, during the last decades this symptom has been the complication of the prolonged 147 
intubation and mechanical ventillation due to traffic accidents, complicated surgical and 148 
intensive care interventions in several hundred thousand cases. This can affect a large part of 149 
the population living in a society with good health care. The cuff of the ventilatory tube may 150 
cause an ulceration on the airway.  151 
Wound healing involves three temporally overlapping stages: an inflammatory stage, a 152 
proliferative stage, and a phase of contraction and remodeling (20). The insult provoking 153 
inflammation and the inflammation itself results the destruction of the intact tissues. In an 154 
ideal case, after the course of inflammation reparative-regenerative processes restore the 155 
integrity of sorrounding tissues, so as a result a sanation of full value is achieved. 156 
Unfortunately, in case of excessive inflammations the regeneration is unable to restore the 157 
original state, therefore in such cases the devastated tissue is replaced by connective tissue 158 
(fibrosis). During the process, the number of inflammatory cells gradually drops in the 159 
inflammatory area, while the number of fibroblasts increases, which are responsible for the 160 
production of connective tissue fibers, and these take over the location of the original 161 
parenchyma. Growth factors (TGF-β) PDGF, FGF) have a decisive role in the formation of 162 
fibrosis, which facilitate proliferation of fibroblasts, the production of matrix and inhibit the 163 
functioning of enzymes decomposing matrices. As the process pushes on, the number of cells 164 
decreases, proportion of the matrix goes up, and finally the fiber-rich scar tissue poor in cells 165 
is being formed (21). Karagiannidis et al. demonstrated the overexpression of TGF-β1 in the 166 
subepithelium. This factor bears a central role in the formation of fibrosis by means of 167 
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rearrangement of extracellular matrix components, morevoer, it is one of the strongest 168 
inductor of myofibroblasts, which have a higher collagen synthesis activity than normal 169 
fibroblasts (27).  170 
1.1.2. Materials and methods 171 
Thus, the process of scarring is determined by a complex inflammatory process. In the 172 
mid-90s a significant trend became widespread for the endoscopic solution of scarry stenoses 173 
(Fig.5.6.) (22). It seemed obvious that the scarring process can be solved in a minimally 174 
invasive manner. But international experience and our own results point out that the restenosis 175 
predisposition is significant, therefore the ultimate definitive solution can often be only 176 
external surgery and the removal of the stenotic part. The endotracheal endoscopic technique, 177 
and, if required, open resection have been used as a routine application for the resolution of 178 
tracheal stenoses at our clinic since 1996 (Fig.1-3.). These interventions enabled us to carry 179 
out the retrospective histological examitation of the removed scarry tracheal segments (n=27) 180 
(Fig.4.). Patients were selected into three groups based on the number and extension of CO2 181 
laser interventions (recanalization) conducted prior to the resection for the elimination of 182 
acute asphyxia. Group 1. is the control group (6 patients), who did not receive laser treatment.  183 
Specimens of patients with max. one described laser treatments were selected into group 2 (12 184 
patients), while specimens of patients with 2-4 extended laser treatments affecting cartilage 185 
were selected into group 3 (9 patients). Histological sections embedded in paraffin were 186 
prepared from the surgical removed specimens, which, apart from the ordinary hematoxilline-187 
eosine staining, were also stained with PAS-AK and examined under light microscope. Our 188 
evaluation covered all three tissue layers of the trachea: epithelium, subepithelium, 189 
cartilage/perichondrium. For the evaluation of the degree of change we set up a 190 
semiquantitative score (0-3). 191 
1.1.3. Results: 192 
Erosion of the epithelium was observed in all three groups, partial regeneration of the 193 
respiratory epithelium (multilayered ciliary epithelium) took place only in three cases of the 194 
control group, in 14 patients squamous metaplasia (Fig.12.) developed, squamous epithelium 195 
was formed to replace the destructed respiratory epithelium. In the third group erosion and 196 
metaplasia appeared in all cases (Fig.7/A,10.12.). A significant difference was observed 197 
between the control group and group 3.  198 
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Irrespectively of the number and extension of laser treatments, inflammation and fibrosis were 200 
expressed in all three groups. The subepithel was characterized by chronic 201 
polymorphonuclear infiltration, and particularly the presence of plasma cells (Fig.7.8.12.) . 202 
The volume of inflammation among patients having received extended laser treatment was 203 
significantly higher than in the control group. The subepithelial layer is characterized by the 204 
tissue image of granulation tissue and intense fibrosis (Fig.8-11.14.15.) in all study groups, 205 
during which fibroblasts appear and produce connective tissue matrices.  206 
  207 
  208 
Figure 16/A-D: Damage levels of the tracheal tissue layers after different degree (groups 209 
1-3) of the endotracheal CO2 laser intervention 210 
The perichondrial fibrosis in the third group was of larger degree as compared to the 211 
control group. As regards the degree of fibrosis, significant difference could be demonstrated 212 
between group 2 and 3. Cartilage necrosis, inflammation destructing cartilage was caused by 213 
the multiple, extended laser treatment. Single laser treatment caused either no or only small-214 
degree cartilage necrosis. However, we observed minimal damage affecting cartilage in only 215 
one case in this group (Fig.16.). Special staining procedures enabled us to characterize certain 216 
tissue-specific changes. Using PAS-AK staining, the older (purple) and young (blue) 217 
connective tissue can be separated (Fig.15.) 218 
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After staining the cartilage matrix red, necrosis was better observable, and in some cases the 219 
formation of new cartilage can be observed, which, being stained blue as a sign of 220 
regeneration, further increases the grade of stenosis (Fig.14.15.) With the application of 221 
Crossmann staining, connective tissue scarring can be characterized as light blue (Fig.9. 10.). 222 
1.1.4. Discussion: 223 
Minimally invasive interventions gaining ground lately involve less burden on 224 
patients. However, in many cases they only result temporary solution to the problem, and, as 225 
histopathological studies proved, in the course of time they further aggravate stenosis. 226 
Contrary to the short-term advantages of laser treatments, their histological analysis showed a 227 
number of negative long-run consequences, many times the mechaism of increased 228 
development of restenosis. In most cases after the epithelial erosion the multilayered ciliary 229 
epithelium did not regenerate on the affected area, therefore the trachea lost its mucociliary 230 
clearance function.  By the increasing of the number and extension if laser interventions, the 231 
occurence and degree of inflammatory, necrotic and fibrotic processes affecting deeper tissue 232 
layers (such as cartilages) rises. Our results histologically confirm clinical observations 233 
stating that there is a connection between the severity of the scarring and the size of the 234 
trauma triggered. Regarding the modern, minimally invasive treatment of stenoses, the above 235 
confirms the necessity to apply microspot and ultrapulse laser techniques offering less tissue 236 
trauma. (23). 237 
The deviations of high volume observed in each therapy groups also indicate other 238 
possible factors affecting the grade of inflammation and fibrosis. Of these, the role of 239 
regulatory factors showing indivudal deviations and determining the scar formation process 240 
on a molecular biological level seems obvious. 241 
 242 
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1.2. Molecular biological studies to assess the genetic predisposition of diseases with 243 
airway scarring   244 
1.2.1. Introduction: 245 
According the literature data, proximately 1-3 % of the prolonged intubations can lead 246 
to significant airway stenosis because of the developed granulation and scar formation. Most 247 
of the obstructions usually close the larynx or the trachea directly, but the difficulty of the 248 
vocal cord movement, the injuries of the laryngeal muscules and joints (scars of the posterior 249 
commisure) can cause suffocation indirectly. The development of the postintubatory stenosis 250 
depend on many circumstances. According to our knowledge external factors, mode and 251 
duration of the intubation play a main role. The general condition of the patient and the 252 
microcirculation of the involved tissues are also considered as determinent factors. The most 253 
recent publications supported the fact that more gentle ventilatory tubes, proton-pump 254 
inhibitors which reduce the gastrooesophageal reflux, local application of fibroblast 255 
proliferation inhibitors can influence the development of the stenosis during intensive care in 256 
favourably. To preserve laryngeal function, the necessity and the timing of the tracheostomy 257 
instead of the translaryngeal ventillation is also an important question. The danger of the 258 
development of the callused airway stenoses can be reduced with these methods, but the 259 
expense of the intensive care increases significantly.  260 
According to our observations after processing a high number of cases refered to our 261 
clinic difference can be found among the patients with similar intubatory circumstances in the 262 
frequency of stenosis. 263 
This brings up a possibility that the different level of scar formation after the damage of the 264 
respiratory mucuos might be explained by different individual regenerative mechanisms, 265 
similarly to the keloid formation already being examined in dermatology, and can also be 266 
explained by genetic predisposition.  267 
Members of the transforming growth factor (TGF) β superfamily are pluripotent 268 
cytokines that modify the growth and differentiation of various cell types. The β1 isoform of 269 
the TGF family (TGFβ1), one of the strongest inducers of myofibroblasts and a mitogen to 270 
immature fibroblasts, appears to be one of the major factors in fibrotic disorders of the human 271 
airway tract. Some of the polymorphisms of the TGFβ1 gene have previously been studied in 272 
diseases of the airway tract associated with fibrotic abnormalities. The fact that some 273 
polymorphisms might both be susceptibility factors for some fibrotic airway disorders and 274 
protective alleles in other disorders implies considerable complexity for TGFβ1 in the 275 
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pathogenesis of these diseases. As recently reported by Lawson and Loyd (1), the 276 
polymorphism at codon 25 (G915C causing an arginine to proline change) has been 277 
associated with post-lung-transplantation allograft fibrosis, but the association of the same 278 
polymorphism with idiopathic pulmonary fibrosis could not be demonstrated. The same 279 
applies to codon 10 (T869C causing a leucine to proline change): it was not associated with 280 
idiopathic pulmonary fibrosis, whereas its association with gas-exchange abnormalities during 281 
the progression of the disease was clear. A very similar modifying effect of codon 10 was 282 
reported by Drumm et al. (24), who demonstrated that cystic fibrosis patients harboring the 283 
codon 10 CC genotype are more prone to severe lung disease. Moreover, their data indicated 284 
that the -509 C/T polymorphism might also contribute to lung complications in cystic fibrosis. 285 
Drum et al. refer to the contrasting data of Wu et al. and Celadon et al. (25-26) observed in 286 
chronic obstructive pulmonary disease (COPD) induced by smoking, which is protected 287 
against by the same codon 10 C and -509 C alleles. The above results on the genetic 288 
background of fibrotic processes in various diseases of the airway tract stimulated us to 289 
conduct an initial study in which we compared the frequency of four TGFβ1 gene 290 
polymorphisms in patients with benign airway stenosis due to endotracheal intubation and in 291 
intensive care patients who had also undergone endotracheal intubation but had never 292 
presented tracheal stenosis. The argument for our ongoing work was supported by the recently 293 
published paper of Karagiannidis et al. (27), in which it was demonstrated that TGFβ1 mRNA 294 
expression was increased in stent-related stenoses as compared with nonstenotic control 295 
sections, as well as a strong matrix-associated subepithelial expression of TGF1 protein. 296 
Moreover, it has been also shown that anterior glottic stenosis (AGS) is also characterized 297 
increased TGFβ1 expression in a canine model system and that chitosan, an effective drug 298 
against AGS significantly down-regulated the expression of TGFβ1 (28) These data suggest 299 
that, similarly to the diseases of the airway tract discussed above, TGFβ1 might be implicated 300 
in the fibrotic abnormalities of the main bronchi, trachea and larynx following mucosal injury 301 
(e.g., stenosis following endotracheal intubation). 302 
 303 
1.2.2. Materials and methods 304 
Sixty-six Caucasian intensive care patients were enrolled in the prospective study 305 
(January 2004 – December 2007) Thirty-six of them were diagnosed with severe 306 
circumferential cricotracheal and tracheal postintubation stenosis (grade III and IV according 307 
to the Myer Cotton classification (29) following endotracheal intubation.  308 
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The consecutive 30 patients, who had never presented scarry airway stenosis in spite of their 309 
long-lasting endotracheal intubation, were regarded as the control population in our study. 310 
They were all treated at the Anesthesiology and Intensive Care Departments of our University 311 
Clinic, therefore this series of patients represents also a homogenious group considering how 312 
endotracheal intubation was carried out. (Table I.) 313 
  314 
Table I. Demographic and clinical characteristics of the enrolled patients 315 
 316 
Genotyping: For our genomic study, venous blood was taken from the patients no other tissue 317 
specimens were collected from them. Genomic DNA was isolated from the blood samples and 318 
polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method 319 
was applied to genotype four polymorhisms of TGFβ1 (Table II.). The PCR products were 320 
size fractionated on agarose gels (Cambrex, Berkshire, UK) and photographed.  321 
The statistical significance of the association between the polymorphisms and postintubation 322 
laryngotracheal stenosis was assessed by means of the Fischer exact probability test and odds 323 
ratios (OR) with 95% confidence intervals (CI) were also calculated (30). 324 
Polymorphism Primers Restriction Enzyme Genotype Distinction 
-800 G/A 
Fwd: CTGGCAGTTGGCGAGAACA 
Rev: TAGAAAGGACAGAAGCGGTG 
MaeIII 
     GG: 326 bp 
     AA: 206+120 bp 
-509 C/T 
Fwd: GGAGAGCAATTCTTACAGGTG 
Rev: TAGGAGAAGGAGGGTCTGTC 
DdeI 
     TT: 120 bp 
     CC: 46+74 bp 
codon10 
Fwd: TCCGGGCTGCGGCTGCAGC 
Rev: CAGGATCTGGCCGCGGATGG 
PvuII 
     TT: 18+135 bp 
     CC: 153 bp 
codon25 
Fwd: TTCAAGACCACCCACCTTCT 
Rev: TCGCGGGTGCTGTTGTACA 
FseI 
     GG: 318+152 bp 
     CC: 500 bp 
 325 
Table II. PCR-RFLP Detection of the TGFβ1 Polymorphisms 326 
  Age (years) Length of intubation (days) 
Patients with acquired 
tracheal stenosis (n=36) 45,8963±17,31 7,87±4,92 
Control patients (n=30) 62,07±16,44 6,93±5,32 
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1.2.3.. Results 327 
The genotype distribution of three TGFβ1 polymorphism (-800 G/A, codon 10 and 328 
codon 25) did not show difference when compared between controls and patients with scarry 329 
airway stenosis. In contracts with these the -509 C/T polymorphism presented a differential 330 
genotype distribution between the affected and control population. As shown in Table III, all 331 
three genotypes of this polymorphism could be detected. The overall allele frequency data 332 
proved to be in good agreement with those recorded for Caucasians in the NCBI internet 333 
databases (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800469): C: 0.68, T: 0.32, 334 
where the genotype distribution is C/C: 0.500, C/T: 0.400 and T/T: 0.100, indicating that 335 
approximately half of the Caucasian population harbors the mutant allele of this locus. Since 336 
the number of homozygous mutants in our study group was extremely low, we excluded them 337 
from the statistical analysis and the proportions of the wild types (C/C) and heterozygous 338 
mutants (C/T) were compared between the benign airway stenosis patient group and the 339 
control group. This comparison revealed that the ratio of heterozygous mutants was 340 
significantly (p=0.0053) higher among the control patients who had undergone long-term 341 
endotracheal intubation but had never presented tracheal stenosis. These data suggest a 342 
protective function for the heterozygous C/T genotype against acquired tracheal stenosis, or 343 
on the other hand, the C/C genotype might be a susceptibility factor for tracheal stenosis in 344 
patients undergoing endotracheal intubation during intensive care (OR=4.5; 95% CI= 1.5123–345 
13.3902). 346 
 347 
A 
Variable No and ratio (%) of patients with the genotype  
 ST C  ST+C 
C/C 21 (0.583)  7 (0.233)  p=0.0116 28 (0.424) 
C/T 14 (0.388) 21 (0.700) OR: 4.5 35 (0.530) 
T/T   1 (0.027)   2 (0.066)   3 (0.045) 
B 
Variable Patients with the allele (%)     
 ST C  ST+C 
C allele 0.777 0.583 p=0.0014 0.689 
T allele 0.222 0.416  0.310 
 348 
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Table III. Distribution of TGFb1 -509 promoter polymorphism genotypes (A) and allele 349 
frequencies (B) between patients with acquired tracheal stenosis (ST; n=36) and control 350 
patients (C; n=30) who underwent long-term endotracheal intubation without 351 
presenting stenosis 352 
 353 
1.2.4. Discussion 354 
Benign airway stenosis is currently considered a multifactorial disorder, in which 355 
primarily the injury of tracheal mucosa and additionally the circumstances of intubation, the 356 
general condition of the patient, the microcirculation of the affected tracheal tissue layers, etc. 357 
are considered to play pivotal roles in the pathogenesis of the disease (31,32). The results of 358 
our present pilot study, however might suggest that, besides these factors, a genetic 359 
predisposition may contribute to the pathogenesis: the presence of the wild type allele of the 360 
TGFβ1 -509 C/T polymorphism. However, the molecular mechanism of the way in which this 361 
polymorphism influences the pathomechanism is still unclear. According to Karaganniadis et 362 
al (27), high-level expression of TGFβ1 mRNA and protein were detectable in biopsy 363 
specimens from stent-related stenosis compared to non-stenotic control sections. Shah and co-364 
workers (33,34) studied the connection between the genotypes of -509 promoter 365 
polymorphism and the level of TGFβ1 mRNA expression and found that the T allele of -509 366 
polymorphism results in high-level mRNA expression. In contrast to this, our present study 367 
demonstrates that heterozygotes for this mutation are somehow less likely to develop 368 
postintubation benign airway stenosis and those having the low expressing C/C genotype are 369 
more likely to develop this diseases. A similar contradiction exists for COPD, where the 370 
TGF1-50β9T allele is protective (25,26),  although it has been also demonstrated that TGFβ1 371 
expression is increased in the airways of COPD patients (35,36). How the -509 T allele of 372 
TGFβ1 evolves its protective effect in COPD and in benign airways stenosis requires further 373 
investigations. The explanation may lie in the bipolar effects of TGFβ1 on immune processes 374 
(37), the complex molecular interactions of TGFβ1 with pro- and antifibrotic proteins (38) or 375 
the extremely broad spectrum of TGFβ1 influences affecting different cell types during 376 
normal wound healing and fibrotic diseases (39). 377 
In relatively developed societies, many individuals in the acute phase of serious 378 
diseases will be subjected to intensive care which may include invasive ventilation. 379 
Accordingly, large numbers of patients are faced with the complications of intubation. One of 380 
the most severe such complication is acquired benign laryngotracheal stenosis, the 381 
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management of which imposes a further serious burden on the patients. Although minimally 382 
invasive treatment options have been developed for some of these stenoses, in most cases 383 
external surgical procedures must be applied as a final measure (28,40). However, all of these 384 
treatment modes involve an increased risk for the patients in the post-intensive period of their 385 
principal disease, so that long-lasting, and sometimes definitive tracheotomy or stenting is 386 
often necessary. 387 
The odds ratio calculated in this pilot study indicated that patients with C/C, who 388 
represents almost the half of the Caucasian population, are 4.5 times more susceptible to 389 
acquired benign airway stenosis. However, there are some age discrepancies in our pilot study 390 
groups, these consecutive series of patients with this high odds ratio for this possible genetic 391 
predisposition may point out practical implications beside the theoretical interest. First of all, 392 
the simple molecular technique used for the detection of this allele makes it feasible as an 393 
everyday molecular diagnostic tool in intensive care. Hence, in the event of the detection of 394 
this genotype, alternative intubation management (e.g., a shorter translaryngeal intubation 395 
period, careful measurement and, if necessary, correction of the cuff pressure, etc.) could be 396 
applied. Furthermore, our data support the suggestion of Karagiannidis et al. (27), that the 397 
targeted inhibition of the profibrotic TGFβ1 could benefit intensive care patients with benign 398 
laryngotracheal stenosis. Last but not least, considering the great differences in allele 399 
frequency between different ethnic groups (e.g.: C: 0.40 and T: 0.60 in Han Chinese vs C: 400 
0.77 and T: 0.23 in African Americans), it is plausible to hypothesize that intensive care 401 
patients from various races might exhibit different susceptibilities toward acquired tracheal 402 
stenosis.  403 
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2. SAFETY AND THERAPEUTIC ASPECTS OF INFLAMMATION-404 
MEDIATING UV LIGHT 405 
 406 
2.1. Effects of intranasal phototherapy on nasal mucosa-safety study 407 
2.1.1. Introduction 408 
One of the main mechanisms of action of UV light is induction of DNA damage in the 409 
irradiated cells. This mechanism is responsible in part for the biological effects of UV light 410 
and consequently its therapeutic use. However, DNA damage is also implicated in the 411 
mutagenic and carcinogenic potential of UV light. Knowledge of the mutagenic risk of DNA 412 
photodamage has stimulated interest to determine the wavelengths dependent distribution of 413 
different DNA photodamage types (41,42) UV light is able to cause DNA damage by direct 414 
mechanisms (absorption of photons by the DNA) or by indirect mechanisms such as 415 
generation of reactive oxygen species (42). Cells possess repair mechanism in response to UV 416 
induced DNA damage. The primary process that removes DNA damage is the nucleotide 417 
excision repair (NER) pathway. The removal of DNA base modifications via NER requires 418 
DNA damage recognition, lesion demarcation, dual asymmetrical incisions at the 50 and 30 419 
sites flanking the lesion, excision of nucleotides from the single-stranded loop, containing the 420 
lesion, and gap-filling by DNA synthesis and ligation (43). Alternatively, highly damaged 421 
cells undergo cell cycle arrest, activation of the caspase cascade and finally apoptotic cell 422 
death (44). 423 
2.1.2. Materials and methods 424 
 Intranasal phototherapy of ragweed allergic patients: The examinations were 425 
performed during the 2005 ragweed season in Szeged, Hungary, in eight ragweed allergic 426 
patients undergoing intranasal phototherapy. Each intranasal cavity was irradiated 3 times a 427 
week for 2 weeks, using gradually increasing doses of mixed ultraviolet and visible light 428 
(mUV/VIS). The irradiations were performed with a broad band light source (Rhinolight®, 429 
Hungary, 180 mW, spectral composition 5% UVB, 25% UVA and 70% visible light). Nasal 430 
cytology samples were collected with a disposable plastic curette (Rhinoprobe®,, ASI, 431 
Arlington, Texas) before starting therapy, immediately after last treatment, 10 days and 2 432 
months after last treatment.  433 
DNA damage detection with COMET assay: DNA strand breaks and alkali-labile sites 434 
were quantified by Comet Assay (single cell gel electrophoresis). As the enzyme, ultraviolet 435 
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DNA endonuclease (UVDE) from Schizosacharomyces pombe participates in an alternative 436 
excision repair pathway in which DNA is cut immediately 50 of CPDs or (6-4) photoproducts, 437 
this endonuclease can be used in Comet Assay for identification and measurement of UV 438 
induced damage. The protocol was a modification of the previously described alkaline Comet 439 
assay (45). 440 
Nasal epithelial cell culture: Positive control experiments were conducted on second 441 
passage nasal epithelial cell cultures, isolated from patients undergoing mucosal resection of 442 
the concha nasi inferior. Cell suspensions and were put in 500 ll PBS and irradiated with 443 
mUV/VIS light with the following doses: 225 mJ/cm2 and 450 mJ/cm2. After irradiation cell 444 
suspensions were collected into Eppendorf tubes and centrifuged at 200g for 4 min and 445 
processed using both the conventional and the UVDE modified Comet assay protocols.  446 
 CPD detection in nasal mucosa: Nasal cytology samples were stained with 447 
monoclonal antibodies against CPDs (anti-thymine dimer, clone KTM53, Kamiya, Seattle, 448 
WA, USA). Control samples were included in each experiment using negative control 449 
reagents that are routinely applied to histologic sections. Immunostaining was performed 450 
using an immunoperoxidase kit (mouse IgG Vectastain Elite ABC kit, Vector Laboratories, 451 
Burlingame, CA, USA). 3,30-diaminobenzidine (DAB) substrate, which results in a brown-452 
colored precipitate, was used as chromogen. The samples were counterstained with 453 
haematoxylin.  454 
Statistical analysis: The data between different time-points were analyzed for 455 
statistical significance using the Dunnett test. To compare the conventional Comet assay with 456 
the UVDE modified technique at the same time points paired t-test was used. Value of p < 457 
0.05 was considered to be statistically significant for comparison between data sets. 458 
 459 
2.1.3. Results  460 
2.1.3.1.1. Kinetics of DNA damage detected by Comet assay in patients undergoing 461 
intranasal phototherapy  462 
Comet assay was performed on nasal cytology samples of eight allergic rhinitis 463 
patients before starting the treatment protocol, immediately after last irradiation and 10 days 464 
after last treatment. Four of the eight patients returned for the 2 month follow-up visit when 465 
nasal cytology samples were collected. DNA damage was significantly higher in nasal 466 
cytology samples collected immediately after completing the 2 weeks treatment regimen than 467 
before starting therapy (p = 0.02 in conventional Comet assay and p = 0.002 in UVDE 468 
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modified assay) (Fig. 17.). DNA damage assessed by the UVDE modified method (49.42 ± 469 
7.97%) was compared with that obtained by the conventional Comet assay (48.48 ± 8.08%) in 470 
samples collected immediately after last treatment.  471 
 472 
   473 
 474 
Figure 17/A: DNA damage detected by conventional and UVDE modified Comet assay 475 
in nasal cytology samples  476 
Figure 17/B: DNA damage detected by conventional and UVDE detected Comet assay in 477 
cultured nasal epithelial cells exposed to UV light 478 
 479 
A slight, but not significant increase was detected in all patients with the UVDE 480 
modified technique compared to the conventional Comet assay (p = 0.7). In positive control 481 
experiments in which nasal epithelial cell cultures were used, a significant increase (p < 0.05) 482 
of UVDE detected DNA damage was observed compared to data obtained by conventional 483 
Comet assay (Fig.17/B). DNA damage of control, non-irradiated nasal epithelial cells was low 484 
and no difference was detected between conventional and UVDE modified Comet assay (5.26 485 
± 1.82% and 6.07 ± 1.43%, respectively). Ten days after the last intranasal treatment a 486 
significant decrease in DNA damage was observed compared to data obtained immediately 487 
after finishing the treatment protocol with the UVDE modified Comet assay method (p = 488 
0.003) (Fig.17/A) and a slight, statistically not significant (p = 0.057) decrease was observed 489 
using the conventional Comet assay technique (Fig.17/A). No significant difference in DNA 490 
damage detected by UVDE modified and conventional Comet assay was observed (p = 0.52) 491 
at this time-point. The difference between baseline (before treatment) and 10 days after last 492 
treatment was not statistically significant (p > 0.05 for both Comet techniques). Four of these 493 
patients were also examined off-season, at the 2 month follow-up. All patients were symptom-494 
free when the samples were collected. The DNA damage detected by both Comet techniques 495 
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was significantly decreased compared to that detected 10 days after last treatment (p = 0.04 in 496 
conventional Comet assay and p = 0.04 in UVDE modified assay) and was similar to 497 
previously reported data from healthy individuals (Fig.17/A) 498 
 499 
2.1.3.2. Kinetics of CPD detection in nasal mucosa of patients undergoing intranasal 500 
phototherapy 501 
Nasal cytology samples of the 8 patients undergoing rhinophototherapy were stained 502 
for CPDs before starting therapy, immediately after last irradiation and 10 days after the last 503 
treatment. None of the samples collected before starting intranasal phototherapy stained 504 
positive for CPDs. In all samples collected immediately after last treatment strong positive 505 
staining for CPDs was detected. The number of positive cells decreased significantly 10 days 506 
after last treatment, but scattered residual positive cells were present in all examined samples. 507 
Cytology samples of 4 patients treated during the season with rhinophototherapy which were 508 
examined off-season (two months follow-up) showed no positive CPD staining cells. (Fig.18). 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
Figure 18.: Detection of CPDs in nasal citology samples, before starting intranasal 517 
phototherapy, immediately after last treatment, 10 days and 2 months after treatment  518 
 519 
2.1.4.. Discussion: 520 
Although, UV light has been previously successfully applied for the treatment of diseases of 521 
the oral and nasal mucosa, no data exist regarding DNA damage and repair of oral and/or 522 
nasal mucosal epithelial cells. The study conducted in allergic rhinitis patients undergoing 523 
intranasal phototherapy is the first assessing UV induced DNA damage in nasal epithelium. 524 
The DNA damage detected by Comet assay in the present study can be attributed in part to 525 
strand brakes as the direct effect of UV on DNA, but may represent also detection of 526 
apoptosis and necrosis not related to UV light. A portion of the cells collected are undergoing 527 
apoptosis or necrosis, which reflects in part physiologic apoptosis occurring in human tissues 528 
related maintainance of normal homeostasis and also cell death due to the procedure of 529 
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collecting cells and most important due to inflammation. DNA repair mechanisms also induce 530 
new strand brakes which are detected by Comet assay (46,47). Considering that at baseline 531 
and immediately after last treatment most of the patients were still symptomatic, Comet assay 532 
results reflect also DNA damage caused by the disease itself and therefore is not detecting UV 533 
specific damage. The addition of the UVDE enzyme increased the specificity of the modified 534 
Comet assay in detecting the UV specific damage attributed to photoproducts (CPDs and 6-4 535 
PPs). This was mirrored by the significantly increased damage detected by the UVDE 536 
modified Comet assay technique in cultured epithelial cells exposed to mUV/VIS light. 537 
Cultured cells exhibited a significantly lower baseline DNA damage level of non-irradiated 538 
cells compared to DNA damage of cells collected from allergic subjects with active disease 539 
state. Although immediately after last treatment a slight increase in DNA damage was 540 
observed in all subjects with the UVDE technique compared to the classical Comet assay, the 541 
difference was not significant. These results suggest a limited contribution of UV specific 542 
DNA damage to the overall cell damage of nasal mucosa in symptomatic allergic rhinitis 543 
patients detected at this time-point with the Comet assay technique. Ten days after last 544 
treatment the DNA damage detected by the UVDE modified technique showed a significant 545 
decrease while the DNA damage detected by the conventional method proved to be not 546 
significant. However, when comparing DNA damage results detected by the UVDE modified 547 
technique with those obtained with the classic Comet assay, no significant difference was 548 
detected. Although, these results suggest that 10 days after last treatment repair of UV 549 
specific photoproducts occurred they also highlight the limitations of Comet assay (both 550 
techniques) in analyzing the superimposed DNA damage (specific to UV light) in an inflamed 551 
nasal mucosa which is characterized by high baseline DNA damage values characteristic to 552 
the disease itself. Therefore, direct detection of UV specific photoproducts by techniques such 553 
as immunostaining of tissue specimens is of outstanding importance for evaluating DNA 554 
damage and repair of nasal mucosa. For an accurate evaluation of the UV specific DNA 555 
damage, CPD staining was performed. Based on the long half life of CPDs and their 556 
persistence in the tissue they are considered the most important photoproducts for 557 
mutagenesis. Our results showed that CPDs can be detected in nasal mucosa samples 558 
immediately after irradiation and residual staining was present 10 days after last irradiation. 559 
These results are in concordance with previously published data in the skin. Samples taken 2 560 
months after the last irradiation showed no residual damage in nasal mucosal samples, 561 
suggesting that after intranasal phototherapy no long-term residual CPDs remain in nasal 562 
cells. Collection of nasal epithelial cells using Rhinoprobes is a very convenient and easy 563 
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technique and have been previously used to asses the effect of air pollution on DNA damage 564 
of nasal mucosa (48-49). However, for a complete evaluation of the safety of phototherapy in 565 
airway diseases the results reported here should be replicated in future studies by staining for 566 
CPDs in biopsy specimens of the nasal mucosa exposed to UV light with special emphasis on 567 
DNA damage and repair of the basal cell layer. UV light-induced carcinogen effect is linked 568 
to the cumulative doses of UV light (usually requiring many years). Development of skin 569 
cancers has always been a concern when applying long-time phototherapy in dermatological 570 
patients. Therefore, several prospective and retrospective studies regarding association of 571 
phototherapy with increased risk for skin cancer have been conducted in psoriasis, atopic 572 
dermatitis and vitiligo patients. Recently, Lee at al performed a complex study based on 573 
extensive literature search (MEDLINE between 1966 and 2002) to asses the risk of skin 574 
cancer associated with UVB phototherapy (50). No significant increase in the risk of 575 
developing skin cancer was found. They stated that evidence suggest that UVB phototherapy 576 
remains a very safe treatment modality. Since skin and mucosa are characterized by 577 
differences in structure and cell turn-over rate we have compared in a separate study the 578 
ability of these tissues to repair UV specific photoproducts (CPDs and 6-4 PPs). We found 579 
that skin and airway mucosa exhibit similar kinetics in repairing UV induced DNA damage 580 
(62). Cumulative doses in rhinophototherapy are lower compared to that used in skin 581 
phototherapy which suggests that the safety profile of mucosal phototherapy is similar to that 582 
of skin. In this pilot study we have shown for the first time that nasal mucosa exposed to UV 583 
light possess the capacity to repair DNA damage which suggests that the multistep process of 584 
carcinogenesis has not been triggered. However more studies are needed in the future to 585 
characterize UV specific DNA damage and repair of the nasal mucosa. 586 
 587 
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2.2. mUV/VIS rhinophototherapy in persistent allergic rhinitis 588 
2.2.1. Introduction 589 
The efficacy of the combined UVB-UVA-high intensity VIS intranasal phototherapy 590 
(Rhinolight®) in seasonal allergic rhinitis was reported by our research work group in a 591 
randomized, double-blind, placebo-controlled clinical study (8). (Medical Research Council 592 
(ETT-TUKEB) certification on the application of Rhinolight® as a medical therapeutic 593 
procedure, file no.: 351/KO/02, certificate no: 60008/20/ETT/2002). 594 
The role of phototherapy in the treatment of perennial allergic rhinitis (PAR) has not 595 
yet been investigated. The aim of our present research was to evaluate the efficacy and safity 596 
of mUV/VIS for the tretament of PAR in a, randomized, double-blind, placebo-controlled 597 
prospective clinical study.  598 
2.2..2. Materials and methods 599 
The target population was represented by PAR patients having moderate or severe 600 
symptoms for at least 4 weeks and occuring at least 4 days a week, with allergies (diagnosed 601 
with a prick test of specific IgE) to house dust mite, mould or (in case or permanent 602 
contanimation) animal epithelial antigen (51). Patients sensitized exclusively to epithelial 603 
antigen were not enrolled. Between November 2007 and March 2008, 34 patients were 604 
included and randomized into our study; 25 patients finished the study (female/male= 7/18; 605 
average age: 34,56 yrs). 9 patients had to be excluded due to upper-airways infection occuring 606 
in the treatment period;data of these patients wasnot included in the assessment. Based on the 607 
inclusion and exclusion criteria, selection of patients took place by rigorously taking into 608 
account the list of prohibited drugs (photosensitizers, non-steroidal anti-inflammatory drugs, 609 
antibiotics etc.), and washout periods (nasal and systemic steroids: 1 month, antihistamine: 2 610 
weeks, oral or intranasal decongestants: 2 weeks, leukotriene antagonists: 1 month).  611 
 The one-month follow-up visit of the last patient was performed inJune, 2008. 612 
Enrollement of patients, randomization and the clinical visits were carried out at the 613 
Department of Otorhinolaryngology and Head-Neck Surgery at the University of Szeged, 614 
while phototherapy, laboratory evaluation of nasal and oral mucosa samples were performed 615 
at the Department of Dermatology and Allergology at the University of Szeged. During the 616 
„run in” period, patients kept a diary of symptoms for a week in the mornings and evenings, 617 
and scored their nasal symptoms on the basis of the preceding 12 hours (on a scale of  0-10).  618 
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If symptom scores were 4 or over for at least two symptoms (of which one had to be either 619 
nasal obstruction or rhinorrhea) during four consecutive days (moderate, severe PAR), the 620 
patient was enrolled (1. visit). Based on randomization three groups were formed: group A: 621 
11 patients (3 droputs) – evaluated number of patients: 8, group B: 10 patients (4 dropouts) - 622 
evaluated number of patients: 6, group C: 13 patients (2 dropouts) - evaluated number of 623 
patients: 11. 624 
During a 6 week period subjects received altogether 13 intranasal phototherapy 625 
treatments (first week 3x/week, then 2x/week for 5 weeks). Based on randomization, , patients 626 
in group A and B received RL treatment(1.6-2.7 J/cm2/nostril/treatment). In group C, similar 627 
to our previous studies, low-intensity visible white light (placebo group) was administered as 628 
a placebo. Treatments were perfomred at the Department of Dermatology and Allergology 629 
between 9 a.m. and 4 p.m., by two trained technicians in turns in a random and standard way, 630 
according to the directives of the Rhinolight® user manual The low intensity visible light 631 
emitting device was obtained by insertion of a special light filterin a Rhinolight device. . In 632 
order to achieve the RL:placebo=2:1 ratio, based on a drawing of lots, one group received 633 
placebo, the other two got RL treatment. Optical settings of the devices were checkedon a 634 
weekly base. Treatment assignment of the groups was only revealed to the patients and the 635 
investigators at the end of the follow-up visits (double blind method). During the treatment 636 
period and the follow-ups, patients kept a diary of symptoms twice a day, right after waking 637 
up and before going to bed, based on the symptoms of the previous 12 hours (rhinorrhea, 638 
nasal itching, sneezing, nasal obstruction, on a scale of 0-10). For the examination of nasal 639 
obstruction the nasal inspiratory peak flow (NIPF) was measured. This is a stable, well-640 
reprodusible, fast and cost-effective method which can be acquired easily by the patient (52). 641 
Patients measured the flow two times a day in their homes (the highest value of three, 642 
previously measurements was recorded each time) using a Youlten (Clement Clark, England) 643 
instrument. 644 
The amount of the rescue  medication (levocetirizin 1x5mg/day.) consumption was recorded, 645 
as well as side-effects and adverse events. Investigators assessed the patients in the 3.week of 646 
the treatments (2. visit), after 24 hours following the end of treatments (3. visit), and after a 647 
month (4. visit) (Table IV.). 648 
 649 
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EVALUATION Screening Inclusion (1. visit) 
Treatment 
phase           
1-6. week 
Treatment 
phase at the 
end of         
3. week         
(2. visit) 
24 hrs after 
last 
treatment  
(3. visit) 
One-month 
follow-up 
control visit 
(4. visit) 
Approval after briefing X 
     
Inclusion/exclusion 
criteria X X 
    
Pregnancy test  X 
  
X 
 
Nasal symptom score /0-
10/ X X X X X X 
Quantitative smell test    X 
  
X X 
Mucociliar transport 
/saccharin test/  X 
  
X X 
ENT examination X 
  
X X X 
NIPF X X X X X X 
Biopsy from nasal 
mucosa  X 
  
X X 
Adverse events     X X X X 
Rescue 
medication/Concomitant 
medication X X X X X X 
 650 
Table IV. Schedule of assessments 651 
 652 
For the quantitative determination of the smell threshold, a standardized Smell 653 
Threshold Test developed by the University of Pennsylvania was used. A thresholds is set out 654 
using a standardized solution series of phenyl-ethyl-alcohol (PEA) stimulating the olfactory 655 
nerve, separately in each nostril, in several steps. The mathematical average of the 656 
concentration values determined during the test are considered to be the threshold 657 
concentration of the given nostril (48). This average is then compared with the previously 658 
determined average values of the age group of a healthy population. The mucociliar transport 659 
function was measured by means of a saccharin test. The saccharin-time shows a good 660 
correlation with the mucociliar function. Mucociliar cells of the nasal mucosa secure the flow 661 
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and transport of mucus.  Saccharimide-Na (3x3 mm) placed on the anterior surface of the 662 
inferior nasal concha it first solutes in the mucus and advances back to the pharynx due to the 663 
mucociliar transport, where it generates a sharp and sweet flavour. The time passing by is 664 
called saccharin-time (11).  665 
Based on a separate patient consent, 18 patients agreed to nasal mucosa sampling for 666 
the determination of ICAM-1 adhesion molecule expression. The ICAM-1 expression of nasal 667 
mucosa epithelial cells is a very sensitive marker of nasal mucosa inflammation in AR 668 
(49,50), therefore it may represent an objective measure for the efficacy of intranasal 669 
phototherapy. Nasal mucosa sam,ples were collected by scraping from the front-lower part of 670 
the inferior nasal concha using the Rhinoprobe®
 
device (56). Samplings were conducted 671 
before the treatment (1. visit), after the completion of the treatement (3. visit) and at the end 672 
of the follow-up phase (4. visit). 7 of the 18 patients examined received placebo, 11 of them 673 
received RL treatment. Percentage figures gained during the 1. sampling were considered as 674 
1, and values gained from the 2. and 3. samplings were correlated to this. Nasal mucosa 675 
epithel cells were used to stain the ICAM-1 (The anti-ICAM-1 antibodies (monoclonal anti-676 
human ICAM-1 Alexa Fluor 647, Santa Cruz Biotechnology) were used.) (54). 677 
Statistical analysis: Using a Repeated Measures ANOVA test, we analysed the change 678 
of RL treatment results compared with placebo results, and the change of values in time at the 679 
end of the treatments and the follow-up period in each groups as compared with the baseline 680 
value. The Fischer LSD (Post hoc) tests (Table V.) was also performed at the end of the 681 
treatment (3. visit) and after the completion of the follow-up phase (4. visit). 682 
2.2.2. Results  683 
Symptom scores for morning and evening nasal symptoms significantly improved 684 
compared to baseline in both groups by the end of the treatment (p<0,05), which lasted until 685 
the end of the one-month follow-up therefore the significant role of time for each symptoms 686 
can be demonstrated using the Repeat Measures ANOVA statistical method. After further 687 
analyzing our data in RL group was compared with Placebo group too (Fischer LSD, post hoc 688 
test). 689 
By the end of treatment symptom scores for morning sneezing (p=0,034), rhninorrhea 690 
(p=0,0019), nasal obstruction (p=0,021), total nasal score (TNS, p=0,019), NIPF (p=0,0019) 691 
and evening sneezing (p=0,017) and NIPF (p=0,0077) showed significant improvement in the 692 
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RL group compared with placebo group. By the end of the four-week follow-up period 693 
morning and evening nasal itching (p=0,004, p=0.0003), evening rhinorrhea (p=0,0034) and 694 
TNS (p=0,0017) scores of the RL group and that of the placebo group reached also statistcial 695 
significance. By the end of the follow-up no significant difference was registered between the 696 
scores of morning and evening sneezing, both of which improved siginficantly by the end of 697 
treatment (p=0,12, p=0,077). Evening nasal obstruction proved to be the most stubborn 698 
symptom. It improved significantly, however, it did not improve significantly compared with 699 
placebo at any time examined.  700 
 
6. week                          
At the end of treatment 
RL vs 
Placebo 
10. week                           
At the end of follow up 
RL vs 
Placebo 
 
RL PLACEBO p RL PLACEBO p 
Sneezing_M -2,16 -1,44 0,03446 -1,97 -1,43 0,12313 
Itching_M -2,04 -1,95 0,78344 -2,40 -1,47 0,00432 
Rhinorrhoea_M -2,46 -1,38 0,00188 -3,16 -1,75 0,00006 
N.obstraction_
M -2,24 -1,52 0,02108 -3,16 -1,99 0,00021 
TNS_M -8,84 -6,30 0,01859 -10,62 -6,66  0,00027 
NIPF_M 19,31 6,79 0,00185 27,28 11,82 0,00007 
Sneezing_E -2,36 -1,57 0,01738 -2,35 -1,72 0,05631 
Itching_E -2,28 -1,95 0,31600 -2,73 -1,53 0,00030 
Rhinorrhoea_E -2,07 -1,54 0,09565 -2,93 -1,99 0,00342 
N.obstarction_E -1,69 -1,47 0,49021 -2,47 -1,91 0,07767 
TNS_E -8,38 -6,54 0,07768 -10,47 -7,19 0,00174 
NIPF_E 20,85 11,56 0,00770 28,14 13,30 0,00003 
 701 
Table V. Average change of nasal symptoms and NIPF as compared with baseline scores 702 
at the end of treatment (6. week), and at the end of the follow-up (10. week)  703 
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  704 
  705 
Figure 19/A-D: Nasal obstruction in the morning, NIPF, rhinorrhea and TNS scores 706 
change based on values registered at baseline, at the end of treatment (6. week) and 707 
follow-up periods (10. week). 708 
 Measured values of the mucociliar function and the quantitative smell threshold 709 
showed a large variations, and no significant change was observed either in the course of 710 
time, or regarding the comparison between the groups (p>0,05). Usage (consumption) of the 711 
rescue medication (in the RL group: 4.21 tbl/person/treatment cycle, in the placebo group: 712 
3,45 tbl/person/treatment cycle) did not was not statistically different in the two group 713 
(p>0,05)ICAM-1 expression, wasdecreased in patients treated with RL compared toplacebo. 714 
This decrease was detected at the end of the tretament period and it became even more 715 
remarkable at the end of the follow-up phase (4. visit), yet it did not reach the significant level 716 
at any time (Figure 20.).  717 
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 718 
Figure 20. Proportion of ICAM-1 positive cells of the nasal mucosa in groups treated 719 
with Rhinolight® and placebo light . 720 
No severe side-effects were observed. Three patients in the RL group reported mild 721 
dryness of the nasal mucosa, which disappeared in a few days after using vitamin A oil. In 722 
both groups 2-2 patients were observed to have mild nose bleed when they blew their nose, 723 
which was not considered directly related to the treatment, and have not requiredtreatment. 724 
Temporary, spontaneously disappearing nasal pain occured in three patients in the RL group, 725 
and two patients in the placebo group, while headache and diarrhea occured in 1-1 patients in 726 
both groups. No difference existed between the frequency of side-effects in the two groups.  727 
2.2.4. Discussion 728 
More than 70% of the Rhinolight® light falls into the range of visible light. The 729 
amount of UV-A light released is below 25%, proportion of UV-B range is less than 5% of 730 
the total light (8,10,57,58). The RL phototherapy inhibits the antigen-induced histamine 731 
release frommast cells, which has been reproted by clinical studies. It induces apoptosis in T-732 
lymphocytes and eosinophil cells, thus reducing the number of eosinophil cells, ECP and 733 
Interleukin-5 levels (57). Based on our previous randomized, placebo-controlled, double-blind 734 
study we found the RL treatment is effective in the treatment of ragweed-induced seasonal 735 
AR (8,53,54). During our current study we aimed to find out whether the RL procedure can be 736 
used in a safe and effective way for moderate and severe PAR. The diary of symptoms kept 737 
by patients served as a basis for the treatment assessment (0-10). Taking into account the 738 
symptoms of the preceding 12 hours, the morning and evening registrations each characterize 739 
separately the severeness of symptoms during the daytime (activity) and the night (resting) 740 
periods. Data collection twice a day promotes the sensitive follow-up of daily, weekly and 741 
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monthly changes in terms of time, as well as the interpretation of individual and occasionally 742 
outstanding values. 743 
Nasal) symptom scores in our PAR patients significantly improved in paralel with the 744 
treatment both in the RL and the placebo group. Significant improvement in the placebo 745 
group may be explained with the fact that continous medical attendance (weekly 3, then 2 746 
treatments, altogether four doctor’s visit and if necessary, and repeated keeping in contact by 747 
phone calls, psychological patient conseilling) can have a significantly positive impact on 748 
subjective symptoms. By the end of treatment and the follow-up periods, morning nasal 749 
obstruction, rhinorrhea, TNS values, and both the morning and evening NIPF, in the RL 750 
treatment group proved to be significantly more effective than placebo light (Table V., Figure 751 
19.). The difference between the two treatment groups (significance levels) further increased 752 
for all the above symptoms and the NPIF values This latter phenomenon can be explained 753 
either with gradual disappearance of the placebo effect of treatments in the follow-up period 754 
or with the efficacy of RL treatments extending beyond the treatment period. These 755 
presumptions are confirmed by the fact that certain symptom scores (nasal itching in the 756 
morning and evening, rhinorrhea in the evening) and the evening TNS values showed 757 
significant difference between those treated with RL and the placebo group by the end of the 758 
follow-up period.  Morning and evening sneezing scores improved by the end of the treatment 759 
in the RL group, but changes proved to be not significant by the end of the follow-up period. 760 
Evening nasal obstruction proved to be the most stubborn symptom as its change did not 761 
reach a significant level by the end of either the treatment or the follow-up period. However, 762 
based on the NIPF values which objectively measures nasal breathing, the RL treatment 763 
proved to be effective in the evening. The frequent contradiction between the subjective 764 
sensation of nasal obstruction and objective parameters describing nasal breathing thus NIPF 765 
values has long been known (60). Similar results were reported by us in seasonal allergic 766 
patients treated for 4 weeks with RL in whichRL treatment proved to be significantly more 767 
efficient than placebo in all nasal symptoms and TNS values, except for nasal obstruction 768 
(8,10,57,58). It must be noted that during this period nasal obstruction scores significantly 769 
decreased in the placebo group. In our current study the sensitivity of symptom changes were 770 
significantly reduced by the well-known fact that in persistent moderate-severe and severe 771 
perennial allergy patients patients symptoms are of less intesity on average, comparedto 772 
seasonal (eg. ragweed) allergic rhinitis,. Patients find it more difficult to evaluate changes of 773 
smaller absolute value during the treatment. The registered improvement of symptoms scores 774 
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exceeding 50% in the placebo group suggests the bilogical efficacy of low-intensity visible 775 
white light (VIS), and it might question its usability as a placebo light. However, previous in 776 
vitro studies on cell cultures unequivocally proved the therapeutic separability of RL and VIS 777 
with regard to the main apoptosis-inducing therapeutic effect (57,59). Based on the results of 778 
these basic studies we applied VIS treatment as placebo in our previous studies and in our 779 
current work. 780 
The objective of our previous safety studies was the determination of the rate of UVB-781 
induced DNA damage and the risk of carcinogenity (61,62). During our study we had an 782 
opportunity for the first time to examine in a standardized way smelling as the physiological 783 
function of the neuroectodermal endonasal epithelium structure which is exposed during the 784 
treatment to UV light (9,53,63). We observed an improving trend in the smell in the RL 785 
tretaed group, which did not reach a significant level. The low number of subjects and the 786 
high varaitions in measurement results made assessment difficult. The improvement observed 787 
can primarily be attributed to the appeasement of allergy symptoms (64,65). No decrease of 788 
smell function was observed in any of the patients, which indicates that intranasal RL 789 
treatment in the applied does not damage the olfactory epithelium. It is worth continuing 790 
observations in seasonal-type allergens, where comparing measurement results made during 791 
the symptomfree period, symptomatic period before treatment, symptomfree periods after 792 
treatment and the season can give us more accurate results. We can examine the impact of 793 
allergic symptoms on smell functions as well as the impact of Rhinolight phototherapy on the 794 
olfactory epithelium with allergic symptoms excluded.  795 
The effect of RL on the mucociliar function has also been examined for the first time. 796 
The saccharin-time indicates shows a good correlation with the mucociliar function . A 797 
number of publications deal with the inhibition of this function by AR, and studies the 798 
regeneration of the reversibly damaged function after the termination of seasonal symptoms 799 
(11). We observed a non-significant improvement of the „mucociliar clearance” function in 800 
the RL group. Phototherapy applied did not affect either the mucociliar or the smell functions 801 
detrimentally, which is another proof for the safety of the RL treatment. Improved the nasal 802 
symptoms because of, reduced the inflammatory processes so decrease the oedema and 803 
secretion of the nasal mucosa. In parallel with this, we expected an improvement in smell and 804 
mucociliar functions, which actually was well observable in a part of the patients, however, 805 
regarding the total treatment groupwe were not able to Show any significant changes. 806 
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We observed a decrease in the number of ICAM-1 positive cells in patients treated 807 
with RL compared with those treated with placebo. The decrease in ICAM-1 expression of the 808 
nasal epithelium in the RL group implies a decrease in the inflammatory process, which 809 
actually coincides with the improvement of the allergy symptoms, however, this difference 810 
was statistically not significant. The high variations observed and the low number of subjects 811 
may be responsible for not reaching statistical significance.  812 
According to clinical observations, if drug treatment (local steroid and/or 813 
antihistamine) is stopped in patients suffering from PAR, they will become more susceptible 814 
to upper-airways infections (51,66). In case of some patients the treatment period unluckily 815 
overlapped with the flu pandemic period, so this can explain that more than a quarter of the 816 
randomized patients had to be excluded from the study due to intercurrent upper-airways 817 
infection.  818 
Nasal dryness observed in the RL group was the only treatment-specific side-effect 819 
(8,10,61), which was not observed in the placebo group. Nasal dryness was not severe, and it 820 
did not increase the likelihood of nasal bleeding. Both our previous studies and experience 821 
gained during clinical practice in seasonal allergic rhinitis showed  a 50-70% incidence of 822 
nasal dryness during the two-week, 3x a week treatment. Our experience suggests that regular 823 
treatment of the nasal mucosa with vitamin-A oil and the 2x a week treatment regimen 824 
reduces the probability of nasal dryness.  825 
Due to the high-rate placebo effect, analysis of differences during the 4-week follow-826 
up is particularly important. When the placebo effect already does not prevail, a significant 827 
difference can be seen between the two groups both for subjective and objective 828 
measurements. Statistical evaluation is mainly difficult due to the low number of cases. A 829 
large multicentric study is neededin order to refine the preliminary results gained so far.   830 
In case of severe symptoms, based on its special mechanism of actionand its good 831 
side-effect profile, the RL phototherapy might be combinedwith other therapeutic modalities. 832 
According to our study, RL phototherapy is also effective in monotherapy for the treatment of 833 
persistent allergic rhinitis. 834 
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2.3.. UV phototherapy of nasal polyps  835 
 836 
2.3.1. Introduction  837 
Immunosuppressive effect of UV light has its most efficient part in the UVB range, so 838 
the so-called narrow-band („narrow-band”, NB-UVB: 305-315nm wavelength) light source is 839 
the one most widely used in phototherapy. It was the research group at the Department of 840 
Dermatology and Allergology at the Universitiy of Szeged to use 308 nm xenon-chloride laser 841 
(XeCl) first to treat psoriasis, vitiligo, and atopic dermatitis (67,68,69).  842 
In some 80% of nasal polyposis cases a persisiting cellular inflammation of 843 
eosinophils is in the background. There are degranulated mastocytes and eosinophils in the 844 
polyp tissue, and the survival period of the latter increased. Deposition of plasma proteins (eg. 845 
albumin) and fibronectin regulated by subepithelial eosinophil infiltration was observed. 846 
Regardless of whether originated from atopic or non-atopic patient, always significantly more 847 
IL-5 can be detected in the polyp tissue than in the control mucosa. IL-5 of growing quantity 848 
and eotaxin can be responsible for the eonisophil cell activation, accumulation and increased 849 
survival, all the above resulted regardless of allergy. However, probably adhesion molecules 850 
also take part in this mechanism (expression of VCAM-1 and VLA-4 are increased). 851 
Presumably TGF-β1 exerts an effect contrary to IL-5, and it is present in the polyp tissue in a 852 
reduced quantity, and can be responsible for the deposition of extracellular matrix proteins 853 
and fibroblast activation. According to a new observation (70) a significant part of patients 854 
have a high amount of  total tissue and multiclonal IgE, and Staphylococcus aureus 855 
enterotoxin  A and B, in addition, there are more asthma and aspirin intolerance patients in 856 
this group. Staphylococcus aureus enterotoxins are pyrogenic proteins of high molecular 857 
weeght, the so-called superantigens, which have a firm T-cell stimulating effect. and induce 858 
cytokine release from macrophages, mastocytes, eosinophil and epithel cells. (71,72). In in 859 
vivo and in vitro studies Staphylococcus aureus enterotoxins can be connected to the measure 860 
of airway hyperactivity and tissue eosinophilia, as well as the severity degree of perennial 861 
rhinitis and asthma, therefore the disease must be regarded as an affecting factor. Based on 862 
another concept (73) similarly to as described in CRS, the inflammatory process develops as a 863 
result of the „failed” elimination reaction launched against fungus antigen detectable in the 864 
nasal lavage of healthy individuals. 865 
 Intranasal phototherapy has been shown to be effective in inflammatory mucosal 866 
diseases such as oral lichen planus and seasonal allergic rhinitis (61,74). The therapeutic 867 
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effect of UVB light is primarily attributed to its local immunomodulatory action. One of the 868 
most important mechanisms that explain the effects of UVB light is induction of apoptosis in 869 
inflammatory cells (57,59,75,76) Therefore, UV phototherapy may represent a new 870 
therapeutic tool for the management of nasal polyps. A pilot feasibility study was performed 871 
to assess the clinical efficacy and tolerability of NB-UVB phototherapy in bilateral nasal 872 
polyps. 873 
2.3.2. Materials and methods 874 
An open-label prospective pilot study was conducted in patients with grade 1-3 nasal 875 
polyps (77). The study was approved by the Central Ethics Committee of Hungary and the 876 
Ethics Committee of University of Szeged. All subjects signed an informed consent. We 877 
excluded potential subjects from the study who had a diagnosis of cystic fibrosis, oral steroid-878 
dependent asthma, or had upper or lower respiratory infection within 4 weeks prior to the 879 
beginning of the study or had any significant nasal structural abnormalities which can 880 
interfere with the delivery of intranasal phototherapy. We also excluded patients with known 881 
photo-sensitivities or photo-allergies to natural or artificial sunlight and those who were 882 
receiving any form of light therapy, or had used any of the following drugs: systemic and 883 
topical corticosteroids, leukotriene modifiers and/or immunosuppressive drugs within 4 884 
weeks, membrane stabilizers and/or antihistamines within 2 weeks, prior to the beginning of 885 
the study.  886 
Patients were exposed to gradually increasing doses of NB-UVB light (300mj/cm2 to 887 
1200mj/cm2) over a 12 week period. UV light was delivered targeted to the nasal polyp tissue 888 
under endoscopic visualization (Allux Medical Inc, Menlo Park, CA, USA). Patients were 889 
treated 3x/week. Subjects rated their nasal obstruction symptom scores weekly on a visual 890 
analogue scale from 0 (none) to 6 (very severe) (77). The NOSE quality of life questionnaire 891 
was used at baseline and end of treatment period (score range from 0 to 100) (78). Adverse 892 
events were monitored by endoscopy. After finishing the treatment period patients had two 893 
follow-up visits, at one and three months after final treatment. At the 1 month follow-up visit 894 
the investigators had the option to prescribe mometasone furoate nasal spray or to keep the 895 
patients without any topical steroids until the 3 month follow-up visit (decision was based on 896 
patients symptoms and endoscopic status). At both follow-up visits symptom scores and the 897 
NOSE questionnaire data were collected. 898 
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 Statistical analysis: The two-sided Dunnett test was used for statistical analysis, p < 899 
0.05 was considered statistically significant. Correlation between nasal obstruction scores and 900 
NOSE scores was assessed by the Pearson correlation test. 901 
2.3.3. Results 902 
Thirteen subjects were enrolled in the study (6 men, 7 women; ages: 38 to 61 years, 903 
mean 47). Ten subjects completed the study, 3 patients dropped out because of non-device 904 
related causes (one subject receiving anticoagulant medication presented spontaneous 905 
bleeding not related to the treatment, one patient with active seasonal allergic rhinitis and 906 
asthma and one patient with superior respiratory tract infection required treatment with 907 
prohibited medication).  From the ten subjects who finished the whole treatment regimen 3 908 
were de-novo nasal polyps and 7 had at least one sinus surgery (performed at least one year 909 
before enrollment).  910 
Nasal obstruction symptom scores significantly improved at end of treatment 911 
compared to baseline (p = 0.009) (Fig. 21/A). Significant improvement of quality of life 912 
(NOSE) at end of treatment compared to baseline was also noted (p = 0.018) (Fig. 21/B). 913 
Changes in nasal obstruction scores showed a good correlation with changes in NOSE scores 914 
(r = 0.81). Treatments were well tolerated and no device related adverse events were reported. 915 
During the one month follow-up period none of the subjects received any treatment, including 916 
intranasal steroids. Nasal obstruction and NOSE scores remained stable during this period 917 
(Fig. 21). A statistically significant difference was observed in nasal obstruction and NOSE 918 
scores recorded at the one month follow-up visit compared to baseline (p = 0.002 for nasal 919 
obstruction and p = 0.001 for NOSE).  920 
 921 
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Figure 21.: Effect of narrow-band UVB phototherapy on nasal obstruction symptom 922 
scores (A) and NOSE scores (B) at end of treatment, 1 month (1 mo FU) and 3 months (3 923 
mo FU) follow-up. 924 
At the one month follow-up no topical steroid was prescribed in seven patients, the 925 
other 3 subjects received mometasone furoate nasal spray. No significant worsening was 926 
observed in nasal obstruction and NOSE scores at the 3 months follow-up visit (Fig. 21.). 927 
Differences between the 3 months follow-up nasal obstruction and NOSE scores and scores 928 
recorded at baseline were statistically significant (p = 0.035 for nasal obstruction and p = 929 
0.015 for NOSE). A detailed analysis showed that subjects with prior sino-nasal surgeries had 930 
a better access to the polyp disease which significantly impacted the therapeutic outcome 931 
(Fig. 22.). 932 
2.3.4. Discussion 933 
Nasal polyps can induce severe symptoms such as nasal obstruction, rhinorrhea and 934 
loss of smell (17). Quality of life of NP patients is severely impaired and it has been shown to 935 
be comparable or even worse than that of patients with chronic obstructive pulmonary 936 
disease, coronary artery disease and asthma (79).  937 
NP is an inflammatory disease with the majority of polyps belonging to the 938 
eosinophilic type. Data suggests that persistence of tissue eosinophilia is of central importance 939 
in the pathogenesis of NP (79,81). Eosinophils are terminally differentiated cells which 940 
differentiate, migrate and accumulate in the tissues following release of various cytokines and 941 
chemokines, such as IL-5, IL-3, GM-CSF, RANTES. These factors can further enhance the 942 
inflammatory process by contributing to stromal fibrosis, epithelial damage, increased edema 943 
and increased extracellular matrix protein production. Thus, eosinophils potentially damage 944 
cells and their prolonged survival in NP is a key factor in the pathogenesis. Apoptosis is 945 
critical in the regulation of eosinophil removal and delayed apoptosis has been reported as an 946 
important mechanism for tissue eosinophilia in several diseases, including nasal polyps (82). 947 
IL-5 is one of the major cytokines which promote eosinophil maturation, activation and 948 
survival. CD4+ T cells are considered to be the major source of IL-5, but other cell types 949 
including mast cells and eosinophils also release this cytokine. In this manner eosinophils 950 
themselves may promote cell survival. Therefore, apoptosis of eosinophils and T cells may 951 
represent a therapeutic target in NP.  952 
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Being an inflammatory disease, treatment of NP is primary medical with anti-953 
inflammatory drugs, such as topical and oral steroids, but even with maximal, well controlled 954 
medical therapy a significant percentage of patients with NP fail and had to undergo sinus 955 
surgery (17). Unfortunately, NP have a strong tendency to recur after surgery even when 956 
aeration is improved and proper medical treatment is administered. NP recurrence rates 957 
reported by different studies vary largely. In their literature review Dalziel et al found that 958 
disease recurrence rate varied from 4% to 60% (median 20%), one major factor responsible 959 
for these differences being the length of the postoperative follow-up (83). Therefore, early 960 
treatment of recurrent disease is of outstanding importance to avoid or significantly delay 961 
further surgeries. 962 
Several studies suggest that apoptosis of inflammatory cells is one of the major 963 
mechanisms of action of systemic and topical corticosteroids (84,85). It has been shown that 964 
long-term treatment of NP with topical corticosteroids reduced the number of eosinophils in 965 
vivo (86). Watanabe et al have shown that increased eosinophil apoptosis is present in NP 966 
cultured in the presence of corticosteroids (87). However, in a recent study Bloom et al have 967 
demonstrated that in the presence of high levels of IL-5, which are more closely related to 968 
those detected in clinical situations, glucocorticoids may actually decrease, rather than 969 
increase, the number of apoptotic eosinophils, suggesting that in in-vivo situations the local 970 
cytokine (or cytokine combination) levels can rescue eosinophils from glucocorticoid-induced 971 
apoptosis (87). Topical corticosteroids are also characterized by limited penetration in the 972 
polyp tissue and are frequently impossible to deliver to problematic areas such as the 973 
ethmoids, sphenoid, frontal and maxillary sinuses. Therefore, despite continuous topical 974 
steroid treatment a significant part of patients show a gradual worsening of the polyp disease. 975 
A modality to reverse the growth of NP and to delay surgery is the use of high dose systemic 976 
steroids (17). Systemic steroids are effective in reducing the severity of symptoms associated 977 
with nasal polyps but are also characterized by strong recurrence tendency and is not unusual 978 
for patients to receive more than one course of systemic steroids per year in the attempt to 979 
delay surgery. Systemic steroids are known for severe side effects especially if used 980 
repeatedly and in higher doses and the medical community is looking for therapies that can 981 
reduce their use in NP (88). 982 
In addition, it has been shown that a subset of NP patients is refractory to corticosteroid 983 
treatment and this can be linked to genetic polymorphism of the glucocorticoid receptor 984 
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(overexpression of the glucocorticoid GRbeta splice variant). Therefore, this population may 985 
be predisposed genetically for medical failure and repetitive surgeries (86) 986 
NB-UVB is considered a gold standard for the treatment of inflammatory skin diseases 987 
and is recommended by guidelines around the world (89,90). The safety profile of NB-UVB 988 
has been widely studied. Recently, Lee et al performed a complex study based on extensive 989 
literature search (MEDLINE between 1966 and 2002) to assess the risk of skin cancer 990 
associated with UVB phototherapy (91). No significant risk of developing skin cancer was 991 
found.  The authors stated that evidence suggests that UVB phototherapy remains a very safe 992 
treatment modality. Recent studies performed on nasal epithelium and in patients receiving 993 
intranasal phototherapy showed that the UV-induced DNA damage response of respiratory 994 
epithelium is very similar to that of the human epidermis. It was also shown that nasal mucosa 995 
is able to efficiently repair UVB induced DNA damage (61,62). These data suggest that 996 
intranasal UVB phototherapy has a similar safety profile as skin phototherapy.  997 
NB-UVB phototherapy may represent an alternative, steroid-sparring treatment for 998 
patients with nasal polyps. The severity of NP has generally been correlated to the degree of 999 
nasal obstruction and therefore any new treatment has to have a significant effect on this 1000 
symptom.  We have shown that both nasal obstruction and quality of life (NOSE) of patients 1001 
improved significantly after NB-UVB phototherapy. The therapeutic outcome was stable for 1002 
at least 3 months after end of treatment despite the fact that most of the patients had not 1003 
received any specific therapy. In the current study the dose of UV light was increased very 1004 
slowly for safety reasons, however the good tolerability suggests that the treatment can be 1005 
started at higher doses and/or the dose escalation may be done in a more rapid fashion which 1006 
would allow achieving clinical results more rapidly. As the treatment is delivered under 1007 
endoscopic visualization, in a targeted fashion, this type of therapy may be especially 1008 
appealing for patients with recurrent disease after sinus surgery. In these patients the 1009 
reconstructed airways allows a better access for delivering the treatment and therapy can be 1010 
applied in a highly controlled way.  1011 
 Our preliminary data suggest that targeted NB-UVB phototherapy may represent a 1012 
promising new therapeutic modality in nasal polyposis especially in patients with previous 1013 
sinus surgeries, but a larger, double-blind study is warranted in the future to assess the 1014 
therapeutic power of a shorter regimen and to further assess the safety profile of this new 1015 
treatment.  1016 
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 1017 
 Figure 22.: Effect of NB-UVB phototherapy in a patient with recurrent polyp 1018 
disease after sinus surgery. Phototherapy significantly improved the disease state 1019 
at end of the treatment period (B) compared to baseline (A) and improvement 1020 
was stable during the 1 month follow-up period (C) 1021 
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CONCLUSION AND NEW RESULTS 1022 
The appearance and course of diseases are determined by genetic and environmental 1023 
factors together. 99% of the genome is the same in every human. The genetic variability 1024 
(heterogenity) accounting for less than 1% determines the individual responses and the 1025 
versatility of biological and physiological processes generated to the same noxa formed in the 1026 
human body, which are traceable with molecular biological methods. Identification of 1027 
etiological factors and knowledge of genome-level predilection factors in modern medicine 1028 
prepares the potential to introduce a custom-made therapy tailored to the individual.  1029 
The better understanding of chronic inflammatory processes taking place in the 1030 
background of airway diseases may contribute to the reassessment of thus far less successful 1031 
treatment methods. Our accurate knowledge allow the creation of new prevention 1032 
programmes and the introduction of modern conservative and minimally invasive therapeutic 1033 
treatment modalities.  1034 
Reviewing the objectives and new results of our studies, let us summarize our 1035 
conclusions: 1036 
 1037 
Hystopathological examination of stenotic, scarry trachea specimens removed with 1038 
cricotracheal resection: 1039 
We have introduced a new semiquantitative method for the classification of the 1040 
hystopathological severity of benign laryngotracheal stenoses, which is capable of evaluating 1041 
the effect of different treatment types. 1042 
The occurence and degree of inflammatory, necrotic and fibrotic processes affecting 1043 
deep tissue layers such as the cartilage increases with the growth of the number and extension 1044 
of endotracheal laser interventions. We have histologically justified the clinical observation 1045 
stating that there is a connection between the severity of the scarring and the size of the 1046 
trauma triggered. 1047 
The deviations of high volume observed in each therapy groups also indicate other 1048 
possible factors affecting the grade of inflammation and fibrosis. Of these, the role of 1049 
regulatory factors showing indivudal deviations and determining the scar formation 1050 
process on a molecular biological level seems obvious. 1051 
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Examination of TGF-β superfamily playing a decisive role in the regulation of inflammatory 1052 
processes, and the predisposition role of its various polymorphisms in the formation of 1053 
laryngotracheal scarring. 1054 
Acquired benign laryngotracheal stenosis associated with abnormal fibrotic processes is 1055 
one of the most severe complications of endotracheal intubation. We aimed to conduct an 1056 
initial study to identify genetic susceptibility factors for this disease. The results of our 1057 
preliminary study suggests that in addition to other factors, genetic predisposition may 1058 
contribute to the pathogenesis of acquired benign laryngotracheal stenosis: the presence 1059 
of the wild type allele of the TGFβ1 -509 C/T polymorphism that has a high rate of 1060 
heterozygosity in the general population may play a role in the pathogenesis of this disease. 1061 
Confirmation our findings by further studies on larger groups of patients may help optimizing 1062 
the intensive patient care to avoid or diminish the risk of this hardly manageable 1063 
complication. 1064 
 1065 
The evaluation the in vivo effect of intranasal phototherapy, by assessing DNA damage and 1066 
repair mechanism in nasal mucosa. 1067 
The DNA-damaging effect of high-energy ultraviolet light irradiation is well known, and 1068 
this effect may indicate the first step of carciogenesis. The majority of literature data refer to 1069 
the damage formed after UV irradiation of the skin, this is why the parallel study of the 1070 
impact exerted by UV light on keratinocytes and nasal epithelial cells is important. We gained 1071 
the epidermal keratinocytes from the skin of donors who had undergone plastic surgery in our 1072 
institute. Nasal epithelial cells were separated and bred from samples of mucosa resection 1073 
surgeries. We detected the measure of UV-induced DNA damage using an alkalic Comet 1074 
assay. During the application of the method, linearly with the raising of UV doses, the extent 1075 
of DNA damage also increased in both cell types, therefore we justified that the Comet assay 1076 
chosen is capable of demonstrating the DNA damage caused by UV light. 1077 
 We detected the effect of the intranasal mUV/VIS phototherapy on DNA damage and 1078 
repair mechanisms in vivo. In our studies, we processed tha nasal mucosa samples of 26 1079 
allergic rhinitis patients in a double-blind experimental system using a Comet assay. Our 1080 
results have shown that in the experimental study design we chose the UV/VIS phototherapy 1081 
did not cause significant DNA damage. 1082 
These results suggest a limited contribution of UV specific DNA damage to the overall 1083 
cell damage of nasal mucosa in symptomatic allergic rhinitis patients detected at this time-1084 
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point with the Comet assay technique. Therefore, direct detection of UV specific 1085 
photoproducts by techniques such as immunostaining of tissue specimens is of outstanding 1086 
importance for evaluating DNA damage and repair of nasal mucosa (CPD staining). Our 1087 
results showed that CPDs can be detected in nasal mucosa samples immediately after 1088 
irradiation and residual staining was present 10 days after last irradiation. We found that skin 1089 
and airway mucosa exhibit similar kinetics in repairing UV induced DNA damage. 1090 
In this pilot study we have shown for the first time that nasal mucosa exposed to UV light 1091 
possess the capacity to repair DNA damage which suggests that the multistep process of 1092 
carcinogenesis has not been triggered. 1093 
 1094 
Preparation of a new therapeutic protocol, establishment of its efficacy and safe usability in 1095 
the treatment of PAR.  1096 
During our current studies we find out whether the RL procedure can be used in a 1097 
safe and effective way for moderate and severe PAR, either. Apart from the improvement of 1098 
subjective nasal symptoms, the NIPF presents the efficacy of the RL phototherapy. Abatement 1099 
of inflammatory processes in the nasal mucosa are also indicated by the decreasing tendency 1100 
of ICAM-1 adhesion molecule expression. Despite using the new, 6-week (13 treatments) 1101 
format of the RL therapy and doubling the total dose (2 weeks/6 treatments), we still did not 1102 
observe any side-effects which were different from that of the placebo. Neither did we observe 1103 
a decrease in either the smelling or the mucociliar functions, which is another proof for the 1104 
safety of the RL therapy. However, it must be noted that due to the heterogenity of the allergic 1105 
patient group, the resumption of studies with large patients numbers involved are necessary 1106 
for the elevation of our results’ value.  1107 
 1108 
The examination of the clinical efficacy and tolerability of NB-UVB phototherapy in bilateral 1109 
nasal polyps 1110 
Our experimental histological studies have justified that UVB penetrates well in vivo 1111 
into the polyp tissue, it reaches in the stroma the lymphocytes responsible for the 1112 
inflammation, and induces apopotosis in them. Intranasal phototherapy showed that the UV-1113 
induced DNA damage response of respiratory epithelium is very similar to that of the human 1114 
epidermis and that nasal mucosa is able to efficiently repair UVB induced DNA damage 1115 
(57,87). NB-UVB phototherapy may represent an alternative, steroid-sparring treatment for 1116 
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patients with nasal polyps. The severity of NP has generally been correlated to the degree of 1117 
nasal obstruction and therefore any new treatment has to have a significant effect on this 1118 
symptom.  We have shown that both nasal obstruction and quality of life (NOSE) of patients 1119 
improved significantly after NB-UVB phototherapy. The therapeutic outcome was stable for 1120 
at least 3 months after end of treatment despite the fact that most of the patients had not 1121 
received any specific therapy. Our preliminary data suggest that targeted NB-UVB 1122 
phototherapy may represent a promising new therapeutic modality in nasal polyposis 1123 
especially in patients with previous sinus surgeries, but a larger, double-blind study is 1124 
warranted in the future to assess the therapeutic power of a shorter regimen and to further 1125 
assess the safety profile of this new treatment. 1126 
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